PEBP1 Knockout A-549 Cell Line
Cat.No.:
EDC08295
Species:
Human
Cell Name:
A-549
Gene:
PEBP1
Gene ID:
5037
Size:
1×10⁶cells
PEBP1 Knockout Cell Line (A549) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC08295 |
|---|---|
| Product Name | PEBP1 Knockout A549 Cell Line |
| Cell Line | A-549 |
| Cellosaurus ID | CVCL_0023 |
| Cell Line Synonyms | A 549, A549, NCI-A549, A549/ATCC, A549 ATCC, A549ATCC, hA549 |
| Gene | PEBP1 |
| NCBI Gene ID | |
| Gene Synonyms | HCNP|HCNPpp|HEL-210|HEL-S-34|HEL-S-96|PBP|PEBP|PEBP-1|RKIP |
| Summary |
This gene encodes a member of the phosphatidylethanolamine-binding family of proteins and has been shown to modulate multiple signaling pathways, including the MAP kinase (MAPK), NF-kappa B, and glycogen synthase kinase-3 (GSK-3) signaling pathways. The encoded protein can be further processed to form a smaller cleavage product, hippocampal cholinergic neurostimulating peptide (HCNP), which may be involved in neural development. This gene has been implicated in numerous human cancers and may act as a metastasis suppressor gene. Multiple pseudogenes of this gene have been identified in the genome. [provided by RefSeq, Jul 2015]
|
| Associated Diseases | Non-Small Cell Lung Carcinoma |
| Morphology | Adherent |
| Passage Ratio | 1/5-1/4 ,2days |
| Complete Culture Medium | F-12K + 10% FBS |
| Freezing Medium | 95% Complete culture medium + 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: A-549 | STR Info (Cell bank) Cell Line: A-549 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | Y | X | Y |
| CSF1PO | 10 | 12 | 10 | 12 |
| D2S1338 | 24 | 24 | ||
| D3S1358 | 16 | 16 | ||
| D5S818 | 11 | 11 | ||
| D7S820 | 8 | 11 | 8 | 11 |
| D8S1179 | 13 | 14 | 13 | 14 |
| D13S317 | 11 | 11 | ||
| D16S539 | 11 | 12 | 11 | 12 |
| D18S51 | 14 | 17 | 14 | 17 |
| D19S433 | 13 | 13 | ||
| D21S11 | 29 | 29 | ||
| FGA | 23 | 23 | ||
| Penta D | 9 | 9 | ||
| Penta E | 7 | 11 | 7 | 11 |
| TH01 | 8 | 9.3 | 8 | 9.3 |
| TPOX | 8 | 11 | 8 | 11 |
| vWA | 14 | 14 | ||
| D6S1043 | 11 | 13 | ||
| D12S391 | 18 | 18 | ||
| D2S441 | 10 | 13 | 10 | 13 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying PEBP1 function, PEBP1 Knockout A-549 Cell Line or PEBP1 overexpression A-549 Cell Line?
The choice depends on whether you are studying PEBP1 (RKIP, Raf kinase inhibitor protein)'s role as a metastasis suppressor in lung cancer or its functions inhibiting Raf-MEK-ERK and NF-κB pathways. The Knockout line is the standard tool for asking whether RKIP is required for these inhibitory functions — RKIP binds and inhibits Raf-1, MEK1, GRK2, and IKK, broadly attenuating proliferative and inflammatory signaling. Overexpression is useful for studying RKIP tumor suppressor functions in lung cancer contexts where RKIP downregulation is associated with metastatic progression.
For lung cancer biology research, the EDITGENE PEBP1 Knockout in A-549 is highly relevant — A-549 is an NSCLC model and RKIP loss has been associated with NSCLC progression and metastasis. This product complements the parallel PEBP1 Knockout in HEK293 (also available); A-549 is preferred for lung cancer-relevant studies, HEK293 for biochemistry. Rescue with wild-type or phospho-RKIP-mimetic (S153D, which switches RKIP from Raf inhibition to GRK2 inhibition) enables comprehensive structure-function studies.
What are the application scenarios for this model?
Primary applications:
• Lung cancer metastasis biology: invasion, migration, and EMT marker analysis in NSCLC context — RKIP loss is associated with NSCLC progression.
• Raf-MEK-ERK pathway hyperactivation: phospho-MEK and phospho-ERK analysis given RKIP's MAPK inhibitory function.
• NF-κB pathway analysis: phospho-IKK, phospho-IκBα, and NF-κB target gene expression.
• EGFR-driven lung cancer studies: RKIP attenuates RTK-driven signaling — assessment of EGFR-TKI sensitivity in RKIP-null lung cancer cells.
EDITGENE recommends this A-549-based model for lung cancer metastasis research; the parallel PEBP1 Knockout in HEK293 (also available) is preferred for biochemical mechanism studies.
Is this PEBP1 Knockout A-549 Cell Line compatible with overexpression rescue experiments?
Yes. RKIP rescue experiments in A-549 are well-suited for lung cancer research:
• Construct design: use a codon-modified PEBP1 sequence with a small C- or N-terminal tag (FLAG, HA). RKIP is small (~21 kDa).
• Phospho-mimetic rescue: S153D mutation mimics PKC-phosphorylated RKIP, switching from Raf to GRK2 inhibition — invaluable for studying RKIP's dual regulation in lung cancer.
• Metastasis-related rescue: assessment of migration/invasion phenotype restoration as functional readout of metastasis suppressor rescue.
• Functional readout: rescue should restore Raf-MEK-ERK pathway attenuation, NF-κB inhibition, and lung cancer-relevant metastatic phenotype suppression.
A-549 transduces efficiently with lentivirus and supports stable rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.